Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Blood Cancer ; 56(3): 379-83, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21225914

ABSTRACT

BACKGROUND: L-2-Hydroxyglutaric aciduria (L-2-HGA) is an uncommon inborn error of metabolism, in which the patients are predisposed to develop brain tumors. Elevated levels of D-2-hydroxyglutarate have been demonstrated with malignant gliomas and myeloid leukemias associated with somatic mutations of the genes encoding NADP(+)-dependent isocitrate dehydrogenases (IDH1 and IDH2, respectively). Recently, we noted a Wilms tumor in a child with L-2-HGA. Given the accumulating evidence that both enantiomers of 2-hydroxyglutarate are associated with cellular transformation, we investigated if sporadic Wilms tumors are associated with IDH1 or IDH2 mutations or with elevated levels of 2-hydroxyglutarate. PROCEDURE: We retrieved 21 frozen Wilms tumor tissues. In 20 cases, we sequenced exon 4 and flanking intronic regions of IDH1 and IDH2. In all 21 cases, we measured 2-hydroxyglutarate levels by liquid chromatography-tandem mass spectrometry. RESULTS: We did not find mutations at the hot spots IDH1 codon 132 or IDH2 codon 172. Two cases (1 with favorable histology and 1 with unfavorable histology) showed heterozygous change c.211G>A (p.Val71Ile) in IDH1, a change previously reported as a mutation but listed as a single nucleotide polymorphism in the NCBI SNP database. We did not find increased levels of 2-hydroxygluatric acid in any sample. CONCLUSIONS: Our results suggest that IDH1 codon 132 or IDH2 codon 172 mutations or elevated 2-hydroxyglutarate levels do not play a role in the biology of sporadic Wilms tumors. The significance of heterozygous change c.211G>A (p.Val71Ile) in IDH1, seen in two tumors, is not clear.


Subject(s)
Glutarates/metabolism , Isocitrate Dehydrogenase/genetics , Mutation/genetics , Wilms Tumor/genetics , Wilms Tumor/metabolism , Child , Child, Preschool , Chromatography, Liquid , DNA Mutational Analysis , Exons/genetics , Female , Humans , Infant , Kidney Neoplasms/genetics , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Male , Prognosis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tandem Mass Spectrometry , Wilms Tumor/pathology
2.
Tumour Biol ; 32(2): 325-33, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21080253

ABSTRACT

Elevated levels of D: -2-hydroxyglutarate (D: -2-HG) occur in gliomas and myeloid leukemias associated with mutations of IDH1 and IDH2. L: -2-Hydroxyglutaric aciduria, an inherited metabolic disorder, predisposes to brain tumors. Therefore, we asked whether sporadic cancers, without IDH1 or IDH2 hot-spot mutations, show elevated 2-hydroxyglutarate levels. We retrieved 15 pairs of frozen papillary thyroid carcinoma (PTC) and adjacent non-neoplastic thyroid, and 14 pairs of hyperplastic nodule (HN) and adjacent non-hyperplastic thyroid. In all lesions, exon 4 sequencing confirmed the absence of known mutations of IDH1 and IDH2. We measured 2-hydroxyglutarate by liquid chromatography-tandem mass spectrometry. Compared to normal thyroid, PTCs had significantly higher D: -2-HG and L: -2-hydroxyglutarate (L: -2-HG) levels, and compared to HNs, PTCs had significantly higher D: -2-HG levels. D: -2-HG/L: -2-HG levels were not significantly different between HNs and normal thyroid. Further studies should clarify if elevated 2-hydroxyglutarate in PTC may be useful as cancer biomarker and evaluate the role of 2-hydroxyglutarate in cancer biology.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Papillary/metabolism , Glutarates/metabolism , Thyroid Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Glutamic Acid/metabolism , Humans , Isocitrate Dehydrogenase/genetics , Isocitrate Dehydrogenase/metabolism , Ketoglutaric Acids/metabolism , Male , Middle Aged , Mutation/genetics , Thyroid Gland/metabolism , Thyroid Nodule/metabolism
3.
Pediatr Dev Pathol ; 13(5): 408-11, 2010.
Article in English | MEDLINE | ID: mdl-20064066

ABSTRACT

We report a male infant with L-2-hydroxyglutaric aciduria and Wilms tumor. L-2-hydroxyglutaric aciduria is a rare, autosomal-recessive, inborn error of metabolism characterized by a variable degree of progressive encephalopathy. Of the fewer than 100 cases reported in the literature, at least 9 patients have developed tumors of the central nervous system. To our knowledge, the present case is the 1st example of an extracranial tumor associated with L-2-hydroxyglutaric aciduria. This observation potentially widens the tumor spectrum in this metabolic disorder and may lead to further insight into the relationship between L-2-hydroxyglutaric acid and cellular transformation.


Subject(s)
Kidney Neoplasms/complications , Wilms Tumor/complications , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Diseases, Metabolic, Inborn/complications , Dactinomycin/administration & dosage , Humans , Infant , Kidney Neoplasms/therapy , Male , Nephrectomy , Vincristine/administration & dosage , Wilms Tumor/therapy
4.
Pediatr Dev Pathol ; 11(2): 128-32, 2008.
Article in English | MEDLINE | ID: mdl-17378665

ABSTRACT

Systemic fetal dysmorphogenesis in disorders of postsqualene cholesterol biosynthesis is thought to be caused by disruption of Hedgehog signaling. Because precholesterol sterols such as 7-dehydrocholesterol and lathosterol can replace cholesterol in the activation of Hedgehog proteins, it is currently believed that cholesterol deficiency-related Hedgehog signaling block occurs further downstream, probably at the level of Smoothened. Experimentally, such a block in Hedgehog signaling occurs at sterol levels of <40 mug/mg protein. Recently, we studied autopsy material from 2 infants with fatal cholesterol biosynthetic disorders (Smith-Lemli-Opitz syndrome and X-linked dominant chondrodysplasia punctata) in which the hepatic cholesterol levels were far greater. In this study, we demonstrate abnormal accumulation of sterol precursors of cholesterol in membrane lipid rafts (detergent resistance membranes) prepared from liver tissues of these 2 infants: 8-dehydrocholesterol and 7-dehydrocholesterol in lipid rafts of the infant with Smith-Lemli-Opitz syndrome and cholest-8(9)-ene-3beta-ol in lipid rafts of the infant with X-linked dominant chondrodysplasia punctata. We suggest that such alterations in the lipid raft sterol environment may affect the biology of cells and the development of fetuses with cholesterol biosynthetic disorders.


Subject(s)
Cholesterol/biosynthesis , Chondrodysplasia Punctata/metabolism , Genetic Diseases, X-Linked/metabolism , Lipid Metabolism, Inborn Errors/metabolism , Smith-Lemli-Opitz Syndrome/metabolism , Cholestadienols/analysis , Cholestadienols/metabolism , Cholesterol/analysis , Cholesterol/metabolism , Chondrodysplasia Punctata/genetics , Chondrodysplasia Punctata/pathology , Dehydrocholesterols/analysis , Dehydrocholesterols/metabolism , Female , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathology , Humans , Infant, Newborn , Lipid Metabolism, Inborn Errors/genetics , Lipid Metabolism, Inborn Errors/pathology , Liver/metabolism , Membrane Microdomains/chemistry , Membrane Microdomains/metabolism , Smith-Lemli-Opitz Syndrome/genetics , Smith-Lemli-Opitz Syndrome/pathology , Syndrome
5.
Pediatr Dev Pathol ; 10(2): 142-8, 2007.
Article in English | MEDLINE | ID: mdl-17378690

ABSTRACT

We recently performed an autopsy on a premature female newborn with rhizomesoacromelic limb shortening of the upper and lower extremities, craniofacial dysmorphism, and chondrodysplasia punctata. A diagnosis of Conradi-Hunermann-Happle syndrome or X-linked dominant chondrodysplasia punctata was made based on elevated cholest-8(9)-ene-3beta-ol in serum and tissues. Molecular analysis of EBP, mutations of which are responsible for this malformation syndrome, revealed a monoallelic missense mutation, c.328 G>A (R110Q). We present this case as an illustration of an unusually severe manifestation of this disorder in a female, with additional unusual features including lack of skin manifestations and apparent bilateral symmetry of the skeletal findings.


Subject(s)
Chondrodysplasia Punctata/diagnosis , Chondrodysplasia Punctata/genetics , Genes, Dominant , Genes, X-Linked , Steroid Isomerases/genetics , Chondrodysplasia Punctata/diagnostic imaging , Chondrodysplasia Punctata/pathology , Fatal Outcome , Female , Humans , Infant, Newborn , Infant, Premature , Models, Biological , Mutation, Missense , Pregnancy , Radiography , Severity of Illness Index , Steroid Isomerases/blood , Steroid Isomerases/metabolism
6.
Mol Genet Metab ; 89(1-2): 74-9, 2006.
Article in English | MEDLINE | ID: mdl-16725361

ABSTRACT

Medium- and short-chain l-3-hydroxy-acyl-CoA dehydrogenase (M/SCHAD) deficiency is a recessively inherited disorder of fatty acid oxidation. Currently, only four patients from three families have been reported in the literature. All these patients presented with hypoglycemia associated with hyperinsulinism (HI). This association suggests that there is a role for M/SCHAD in regulating the pancreatic secretion of insulin. We present a fifth patient whose presentation was similar to Reye syndrome, a feature in common with most of the previously recognized disorders of fatty acid oxidation but with no clinical evidence of HI. Sequencing of the HAD1 gene on chromosome 4 revealed compound heterozygosity for two novel missense mutations, 170A>G, resulting in D45G, and 676T>C, resulting in Y214H. The mutant enzymes were expressed and subjected to kinetic analysis. Y214H has no detectable activity, whilst D45G, which resides in the cofactor-binding pocket, has an altered K(m) for NADH (96 microM versus 24 microM for the wild-type). This represents the first kinetic M/SCHAD mutant, which explains the high residual activity in skin fibroblasts. The lack of obvious HI in this patient may be related to the high residual activity and indicates that HI associated with M/SCHAD deficiency may only be present with complete deficiency. The spectrum of M/SCHAD phenotype should be broadened to include acute liver disease.


Subject(s)
3-Hydroxyacyl CoA Dehydrogenases/genetics , Reye Syndrome/diagnosis , Reye Syndrome/genetics , 3-Hydroxyacyl CoA Dehydrogenases/analysis , 3-Hydroxyacyl CoA Dehydrogenases/chemistry , DNA Mutational Analysis , Female , Heterozygote , Humans , Infant , Kinetics , Mitochondria/enzymology , Mutation, Missense , Protein Conformation
8.
Mol Genet Metab ; 82(1): 59-63, 2004 May.
Article in English | MEDLINE | ID: mdl-15110323

ABSTRACT

Liver carnitine palmitoyltransferase I (CPT I) deficiency is a rare disorder of hepatic mitochondrial long-chain fatty acid oxidation. It characteristically presents with symptoms associated with failure of ketogenesis (hypoketotic hypoglycemia). The disorder is due to mutations in the CPT 1A gene for which few patients have been characterized. We present here four novel mutations in five patients from four families with severe enzyme deficiency. Three of these are missense mutations (G465W, R316G, and F343V) and the fourth a nonsense mutation (R160X). Other than small Inuit and Hutterite populations in Canada and the Northern plains, there is complete heterogeneity of disease-causing mutations within CPT I deficient families with each demonstrating unique mutations. Because there are no easily recognizable disease-specific metabolite markers, diagnostic confirmation of this disorder requires a combination of enzymatic analysis and whole gene sequencing.


Subject(s)
Carnitine O-Palmitoyltransferase/deficiency , Carnitine O-Palmitoyltransferase/genetics , Lipid Metabolism, Inborn Errors/genetics , Liver/enzymology , Mitochondrial Diseases/genetics , Mutation/genetics , Adolescent , Child , Child, Preschool , DNA Mutational Analysis , Female , Fibroblasts/metabolism , Humans , Hypoglycemia/genetics , Infant , Ketones/metabolism , Lipid Metabolism, Inborn Errors/diagnosis , Male , Mitochondrial Diseases/diagnosis , Polymorphism, Genetic/genetics , Sequence Analysis, DNA , Syndrome
9.
Pediatr Res ; 53(5): 788-92, 2003 May.
Article in English | MEDLINE | ID: mdl-12621117

ABSTRACT

Adriamycin (ADR) inhibits the carnitine palmitoyl transferase (CPT) system and consequently the transport of long-chain fatty acids across mitochondrial membranes. l-Carnitine (CARN) plays a major role in fatty acid oxidation by translocating activated long-chain fatty acids into the matrix of mitochondria. CARN has been shown to be of benefit in certain cardiac conditions including cardiomyopathy and myocardial infarction. This study was devised to investigate the effect of CARN on altered CPT I and CPT II activity in the cardiomyopathy associated with ADR therapy. We also assessed the effect of CARN on the plasma free, total, and acylcarnitine concentrations. Four groups, each consisting of four male Sprague-Dawley rats, were studied: group 1(n = 4) was not given either ADR or CARN; group 2 (n = 4) was given ADR (15 and 20 mg/kg, respectively, cumulative dose) by i.p. injections for 1 and 2 wk; group 3 (n = 4) was given the same dose of ADR with CARN (200 mg/kg); and group 4 (n = 4) was given CARN (200 mg/kg). The activities of CPT I and CPT II in heart were significantly decreased in the ADR-treated rats (p < 0.05) in a dose-dependent manner. The reduced activities of CPT I and CPT II, inhibited by ADR, were not normalized by supplementation with CARN (p < 0.05). In rats supplemented with CARN alone, the activities of CPT I and CPT II were elevated approximately 50% above those of the control rats (p < 0.05). ADR treatment resulted in elevation of plasma free and total CARN concentrations (p < 0.05). Supplementation with CARN did not effect the increased plasma CARN concentrations resulting from ADR treatment (p < 0.05). This study supports the concept that ADR toxicity results from the inhibition of both CPT I and CPT II activities and that one of the causes of ADR-induced cardiomyopathy is a result of globally impaired fatty acid oxidation.


Subject(s)
Cardiomyopathies/drug therapy , Carnitine O-Palmitoyltransferase/metabolism , Carnitine/pharmacology , Myocardium/enzymology , Animals , Antibiotics, Antineoplastic/pharmacology , Cardiomyopathies/metabolism , Carnitine/blood , Dose-Response Relationship, Drug , Doxorubicin/pharmacology , Enzyme Activation/drug effects , Male , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...